Epicrispr secures $90M after early data on epigenetic FSHD treatment
Epicrispr Biotechnologies has raised $90 million for its Series C round after sharing promising early data around a potential new way to treat a rare muscle disease called facioscapulohumeral muscular dystrophy. The Series C was ...
Amber Salzman, Epicrispr CEO August 11, 2026 08:54 AM EDT FinancingR&D Epicrispr secures $90M after early data on epigenetic FSHD treatment Lei Lei Wu News Reporter Epicrispr Biotechnologies has raised $90 million for its Series C round after sharing promising early data around a potential new way to treat a rare … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that